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The most common admission indication in cardiology prac-
tice is acute coronary syndrome with or without ST-segment
elevation. In patients presenting with ST-segment elevation at
admission, ECG reperfusion therapy is instituted as fast as
possible [1–3], which can be accomplished by primary PCI,
by fibrinolysis, or both. This results in a significant reduction
in infarct size and improvement of short- and long-term prog-
nosis [2, 3]. In patients with coronary syndromes presenting
without ST-segment elevation on the admission ECG, anti-
ischaemic and antithrombotic therapies are also of utmost
importance. However, in the last decade a strong switch has
been seen in the invasive approach to this condition. Angiog-
raphy can improve risk stratification and, if indicated,
revascularisation can be planned. Several randomised trials
have evaluated a routine invasive strategy in comparison to a
more selective invasive approach in these patients. The out-
come results were mixed [4–6]. Although these meta-analyses
included trials from the pre-clopidogrel era, a routine invasive
strategy showed a reduction in myocardial infarction and
repeat intervention. The results with regard to early and
long-term survival were also variable. There seemed to be
an early hazard for early mortality compensated by a later
reduction [4].
The substrate of a non-ST-elevation myocardial in-
farction does not usually consist of an acutely occluded
epicardial coronary artery as in ST-segment-elevation
myocardial infarction. In non-ST-elevation acute coro-
nary syndromes (NSTE-ACS) there can be severe but
non-occlusive coronary artery disease, or no disease at
all. In the large TACTICS-TIMI-18 study nearly half of
the patients had left main or triple vessel disease and
only 13 % had normal coronary arteries [7]. In both
instances reperfusion therapy is not indicated and only
leads to harm by bleeding and excess myocardial in-
farction [8, 9].
The cornerstone of the treatment of patients undergoing
coronary stenting for acute coronary syndromes is dual
antiplatelet therapy with aspirin and the platelet P2Y12
receptor antagonist clopidogrel. Consequently, many pa-
tients in cardiology practice in 2013 are on dual antiplatelet
therapy, mainly aspirin and clopidogrel. The only important
side effect of dual antiplatelet therapy is increased bleeding
in comparison with aspirin alone. This has been established
in the large trials with clopidogrel in ACS [10, 11] and
thereafter [12], also in atrial fibrillation [13]. Especially in
the latter dual antiplatelet therapy has shown to be as
hazardous as oral anticoagulation [14]. The novel platelet
P2Y12 receptor antagonists prasugrel and ticagrelor are
more effective than clopidogrel in patients, but show more
major bleeding including intracranial haemorrhage [15,
16]. Prasugrel is specifically indicated and registered for
use after PCI for ACS.
In today’s issue of the Netherlands Heart Journal, the
design of a study on adherence to evidence-based med-
icine in a large group of patients discharged after ACS
is described [17]. The strength of the paper is that the
study is (a) carried out in a large single region, (b)
prospective in nature and (c) part of a thorough registry.
In this registry the new oral antiplatelet drug prasugrel
will be used. The interim results of this study are now
available online and will be published in a forthcoming
edition of the journal [18].
Of course, the weakness of the registry is the potential
confounding bias, which is inherent to every registry, even
the prospective ones. A randomised comparison with e.g.
ticagrelor or even clopidogrel would, therefore, be preferable,
but randomised controlled trials have the severe shortcoming
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of selection bias (Table 1). For a long time now, meta-analyses
have been used to evaluate treatment effects of certain medical
strategies in a broader perspective. However, meta-analyses
not only suffer from publication bias and, therefore, may
overestimate a treatment effect, they often also show consid-
erable heterogeneity. Unfortunately, many guidelines appreci-
ate meta-analyses as level of evidence similar to that of
individual randomised controlled trials. Given the above, this
must be discouraged. At best, meta-analyses are hypothesis
generating, and should not be used to underscore the weight of
a cluster of individual randomised trials. Even in the absence
of properly randomised studies with enough power, meta-
analyses should be omitted from guidelines when it comes
to weighing level of evidence. Both randomised studies and
registries for medical procedures are of the utmost importance.
Although clinical trialists despise observational studies be-
cause of the confounding factors, they should admit that they
represent the real world provided all incident NSTE-ACS
cases are entered into the registries For that purpose, only
prospective registries are acceptable for therapy evaluation.
The current design paper meets this criterion.
In conclusion, the design of a registry presented in this
issue is a solid basis for the collection of evidence-based
discharge strategies after ACS. However, a new antiplatelet
drug will be used in the registry for the patients treated with
PCI for their index ACS. This may be a confounded registry,
in that prasugrel can be used exclusively in patients without
contraindications to the agent (age, prior stroke and low body
weight). In that case clopidogrel or ticagrelor may be pre-
ferred. And hopefully pre-treatment with prasugrel will be
avoided, since it is not helpful and causes increased bleeding
[19]. But given the excellent past clinical performance of the
study group it will implement the most recent study data into
their practice.
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